skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8129

Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia

Original Research

(2319) Views  (899) Full article downloads

Author: Andrew Thomson

Published Date June 2005 Volume 2005:1-Issues 1 & 2(2) Pages 0 - 0
DOI: http://dx.doi.org/10.2147/CE.S7414

Andrew Thomson

Core Medical Publishing, Knutsford, UK

Introduction: Benign prostatic hyperplasia (BPH) is a common condition affecting older men. Bothersome symptoms can progress to serious complications such as acute urinary retention (AUR) requiring surgical intervention. Dutasteride, a dual 5-alfa-reductase (5AR) inhibitor (5ARI), is a recently introduced therapy for the treatment of BPH.

Aims: The objective of this article is to review the evidence for the treatment of BPH with dutasteride.

Evidence review: Evidence from large clinical studies shows that men with an enlarged prostate achieve a measurable decrease in prostate volume by up to 26% after 4 years of treatment with dutasteride and urinary symptoms improve after 6 months of treatment. This is achieved by rapid suppression (through inhibition of 5AR) of the principal androgen (dihydrotestosterone or DHT) responsible for stimulating prostatic growth. Evidence suggests that dutasteride treatment results in a reduction in risk (rather than delay) of the most serious complications including episodes of AUR and the need for BPH-related surgery. Early symptom relief has been achieved with the combination of an alfa blocker and dutasteride. There is good evidence that dutasteride is well tolerated; side effects limited to sexual dysfunction (reduced libido, impotence, and gynecomastia) are more common compared with placebo but occur with a similar incidence to finasteride, another 5ARI. No pharmacoeconomic evidence from studies with dutasteride has so far been published.

Clinical value: In conclusion, dutasteride is a valuable treatment option in men with moderate to severe BPH. Reductions in prostate volume lead to symptom relief and serious complications appear to be reduced.

Key words: dutasteride, evidence-based review, benign prostatic hyperplasia (BPH), 5-alfa-reductase inhibitor






 

Other articles by Dr Core Journal

Aliskiren in hypertension: evidence for its potential therapeutic value
Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting
Aripiprazole: the evidence of its therapeutic impact in schizophrenia
Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer
Bortezomib: the evidence of its clinical impact in multiple myeloma
Ciclesonide in persistent asthma: the evidence of its therapeutic value
Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia
Donepezil in Alzheimer’s disease: an evidence-based review of its impact on clinical and economic outcomes
Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopenia
Eplerenone: the evidence for its place in the treatment of heart failure after myocardial infarction
Etanercept in psoriasis: the evidence of its therapeutic impact
Exubera® (inhaled insulin): an evidence-based review of its effectiveness in the management of diabetes
Fosphenytoin for the treatment of status epilepticus: an evidence-based assessment of its clinical and economic outcomes
FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value
K-111: the emerging evidence for its potential in the treatment of the metabolic syndrome
Lapatinib: the evidence for its therapeutic value in metastatic breast cancer
Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis
Maraviroc: the evidence for its potential in the management of HIV
Perindopril: the evidence of its therapeutic impact in hypertension
Pramipexole in restless legs syndrome: an evidence-based review of its effectiveness on clinical outcomes
Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome
Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value
Tigecycline: an evidence-based review of its antibacterial activity and effectiveness in complicated skin and soft tissue and intraabdominal infections
Topiramate: the evidence for its therapeutic value in the prevention of migraine
Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University